Illumina (ILMN) – StreetInsider.com Reports
-
Illumina (ILMN) PT Lowered to $125 at Baird
-
Illumina (ILMN) Divestment of GRAIL Approved in EU
-
Illumina (ILMN) PT Raised to $100 at Barclays
-
Illumina (ILMN) appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer
-
EU merger powers may be curbed after court adviser backs Illumina fight
-
OTR Global Downgrades Illumina (ILMN) to Mixed
-
Evercore Positive on a these names following 'China stimulus for hospital & teaching equipment'
-
Illumina shares fall as Ichan reportedly abandons second proxy contest
-
Exclusive-Icahn drops Illumina board challenge threat, sources say
-
Carl Icahn Drops Threat to Challenge Illumina's (NASDAQ: ILMN) Board - Reuters
-
Icahn Enterprises (IEP) Names Andrew Teno as Chief Executive Officer
-
Illumina (ILMN) PT Raised to $135 at JPMorgan
-
Illumina (ILMN) PT Raised to $105 at BofA Securities
-
Illumina (ILMN) PT Raised to $150 at TD Cowen
-
Illumina (ILMN) PT Raised to $145 at UBS
-
Illumina (ILMN) PT Raised to $146 at Baird
-
Illumina (ILMN) PT Raised to $160 at Stifel
-
Illumina (ILMN) PT Raised to $145 at Citi
-
Illumina (ILMN) PT Raised to $85 at Barclays
-
Illumina forecasts flat 2024 sales as sluggish demand drags on
-
Illumina (ILMN) Tops Q4 EPS by 13c; offers guidance
-
Illumina (ILMN) option IV elevated into quarter results and outlook
-
Illumina (ILMN) February weekly 143 straddle into quarter results
-
Illumina (ILMN) call put ratio 7.8 calls to 1 put
-
Illumina (ILMN) February weekly 145 straddle priced into quarter results
-
Illumina (ILMN) PT Raised to $144 at Baird
-
Illumina (ILMN) PT Raised to $80 at Barclays
-
Illumina (ILMN) PT Raised to $130 at Canaccord Genuity
-
Wolfe Makes Adjustments to Alpha List
-
HSBC Downgrades Illumina (ILMN) to Hold
-
Illumina unveils preliminary fourth-quarter revenue that tops estimates
-
Illumina (ILMN) Prelim. Q4 Revenue Tops Consensus
-
Illumina (ILMN) Expand Collaboration with Janssen for Molecular Residual Disease Cancer Test
-
Illumina (ILMN) Announces Departure of Chief Commercial Officer
-
Pfizer (PFE) and Illumina (ILMN) downgraded but Merck (MRK) can deliver, declares TD Cowen
-
TD Cowen Downgrades Illumina (ILMN) to Market Perform
-
Madryn Asset Management Calls Against SomaLogic’s (SLGC) 'Value-Destructive Proposed Merger' with Standard BioTools (LAB)
-
Illumina (ILMN) PT Lowered to $258 at RBC Capital
-
Icahn is Said Ready to Launch Fight to Control Illumina's Board - Bloomberg
-
Midday movers: Apple, Netflix and more
-
Activist Icahn prepares a second board challenge at Illumina -letter
-
Scotiabank Upgrades Illumina (ILMN) to Sector Outperform
-
Illumina rises premarket after gene-sequencing group announces Grail divestiture
-
Futures edge up, Illumina to divest Grail - what's moving markets
-
Illumina (ILMN) to divest Grail
-
Bernstein Upgrades Illumina (ILMN) to Market Perform
-
Guggenheim Starts Illumina (ILMN) at Buy
-
Stephens Starts Illumina (ILMN) at Overweight, 'Divestiture Unlocks Value'
-
Wolfe Research Starts Illumina (ILMN) at Outperform
-
BofA Securities Downgrades Illumina (ILMN) to Underperform, 'With 4 years of no growth, we see no imminent fix'
Back to ILMN Stock Lookup